Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: Effect of cyclosporine

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 261-266

  Westley, Ian S ^a,c   Brogan, Leonie R ^c   Morris, Raymond G ^a,b   Evans, Allan M ^c   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYBUTOXY MYCOPHENOLIC ACID; CYCLOSPORIN A; DRUG METABOLITE; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID ACYLGLUCURONIDE; MYCOPHENOLIC ACID ETHER GLUCURONIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE SECRETION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; ISOLATED LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; BILIARY TRACT; CYCLOSPORINE; DRUG INTERACTIONS; GLUCURONIDES; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 31444448077     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.006122     Document Type: Article

References (40)

1. Akhlaghi F and Trull A (2002) Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 41:615-637.
2. Bohme M, Buchler M, Muller M, and Keppler D (1993) Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett 333:193-196.
3. Bowalgaha K and Miners J (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
4. Brown NW, Aw MM, Mieli-Vergani G, Dhawan A, and Tredger JM (2002) Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. Ther Drug Monit 24:598-606.
5. Bullingham R, Monroe S, and Nicholls A (1996a) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after a single-dose oral and intravenous administration. J Clin Pharmacol 36:315-324.
6. Bullingham R, Nicholls A, and Hale M (1996b) Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28:925-929.
7. Chiang J (2003) Bile acid regulation of hepatic physiology 3. Bile acids and nuclear receptors. Am J Physiol 284:G349-G356.
8. Fahr A (1993) Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24:472-495.
9. Filler G, Lepage N, Deliste B, and Mai I (2001) Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23:514-519.
10. Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB, Kliewer SA, Gonzalez FJ, and Sinal CJ (2003) Complementary roles of farnesoid X receptor, pregnane X receptor and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278:45062-45071.
11. Haimeur A, Conseil G, Deeley R, and Cole S (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-53.
12. Hesselink D, van Hest R, Mathot R, Bonthuis F, Weimar W, de Bruin R, and van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987-994.
13. Jager W, Sartori M, Herzog W, and Thalhammer T (1998) Genistein metabolism in liver microsomes of Wistar and mutant TR(-) rats. Res Commun Mol Pathol Pharmacol 100:105-116.
14. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, and Keppler D (1999) Transport of monoglucuronosyl and bisglucuronsyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30:485-490.
15. Keown P, Landsberg D, Shapiro J, Halloran P, Cole E, Zaltzman J, and Muirhead N (2001) Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 72:1024-1032.
16. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi K, and Hirano T (2004) Cyclosporin A but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029-1035.
17. Kohlhaw K, Christians U, Surig T, Lamesch P, Hauss J, Sewing K, and Pichlmayr R (1994) Cyclosporine and bilirubin metabolites compete for the hepatic excretory system. Transplant Proc 26:2798-2799.
18. Kuypers D, Vanrenterghem Y, Squifflet J, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, and Daems J (2003) Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 25:609-622.
19. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
20. Nishino A, Kato Y, Igarashi T, and Sugiyama Y (2000) Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin 2 antagonist, telmisartan. Drug Metab Dispos 28:1146-1148.
21. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase 2 metabolism. Drug Metab Dispos 33:139-146.
22. Pillans P, Rigby R, and Kubler P (2001) A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem 34:77-81.
23. Roman I, Fernandez-Moreno M, Fueyo J, Roma M, and Coleman R (2003) Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol Sci 71:276-281.
24. Sallustio B, Fairchild B, Shanahan K, Evans A, and Nation R (1996) Disposition of gemfibrozil and genfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab Dispos 24:984-989.
25. Schutz E, Shipkova M, and Armstrong V (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45:419-422.
26. Sewing K, Christians U, Kohlhaw K, Radeke H, Strohmeyer S, Kownatzki R, Budniak J, Schottmann R, Bleck J, Almeida V, et al. (1990) Biological activity of cyclosporine metabolites. Transplant Proc 22:1129-1134.
27. Shipkova M, Armstrong V, and EW (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Clin Pharmacol 126:1075-1082.
28. Shipkova M, Wieland E, Schutz E, Weiss C, Niedmann P, Oellerich M, and Armstrong V (2001) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33:1080-1081.
29. Shitara Y, Itoh T, Sato H, Li A, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between Cerivastatin and Cyclosporin A. J Pharmacol Exp Ther 304:610-616.
30. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier P, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat Oatp1 (Slc21a1)- and Oatp2 (Slc21a5)- mediated transport. Pharm Res (NY) 19:147-153.
31. Smak Gregoor P, van Gelder T, Hesse C, van der Mast B, van Besouw N, and Weimar W (1999) Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dialysis Transplant 14:706-708.
32. Soroka CJ, Lee JM, Azzaroli F, and Boyer JL (2001) Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology 33:783-791.
33. Strassburg C, Barut A, Obermayer-Strauss P, Li Q, Nguyen N, Tukey R, and Manns M (2001) Identification of cyclosporine A and tacrolimus glucuronidation in human and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 34:865-872.
34. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
35. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
36. van Gelder T, Klupp J, Barten M, Christians U, and Morris R (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119-128.
37. Westley I, Sallustio B, and Morris R (2005) Validation of a high performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem 38/9:824-829.
38. Wieland W, Shipkova M, Schellhass U, Schutz E, Niedmann P, Armstrong V, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects. Clin Biochem 33:107-113.
39. Xiong H, Turner K, Ward E, Jansen P, and Brouwer K (2000) Altered hepatobiliary disposition of acetoaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR- rats. J Pharmacol Exp Ther 295:512-518.
40. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, and Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35-43.